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ABSTRACT 
Objective: Failure to clear oral secretions can be debilitating for patients with amyotrophic 
lateral sclerosis, ALS, but the treatment of this symptom is poorly defined and there is no 
consensus on best practice. The objective of this study was to identify the treatments that 
are commonly prescribed, and to describe how experienced clinicians manage a patient 
with treatment resistant symptoms. 
Methods: Twenty-three clinicians were approached, of which 19 from 16 centres across the 
UK provided case report forms for a total of 119 ALS patients identified as having 
problematic oral secretions. 
Results: The use of five anticholinergics, salivary gland botulinum toxin injections, 
conservative management approaches and carbocisteine were reported.  Of the 72 patients 
who were evaluated following the initiation of a first anticholinergic, 61% had symptomatic 
improvement. Only 19% of patients achieved symptomatic improvement with the use of an 
alternative anticholinergic when an initial anticholinergic achieved no symptomatic 
improvement. Problems with thick and thin secretions often co-existed with 37% of patients 
receiving treatment for both types of problem.  
Conclusion: A variety of treatment options are employed by expert clinicians for problematic 
oral secretions in ALS patients. The variation in management highlights the need for further 
prospective research in this area.  
Search terms: Secretion management, sialorrhea, anticholinergics, botulinum toxin
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
affecting the motor nerves supplying the limbs, trunk, bulbar region and respiratory 
muscles [1].  It has been estimated that 50% of ALS patients suffer from problematic 
oral secretions and a recent survey of clinicians estimated that in 42% of patients 
with secretion problems, these problems are poorly controlled [2].Symptoms and 
consequences include drooling (sialorrhoea), breakdown of the skin around the 
mouth, speech disturbance, disruption of sleep, coughing and a higher risk of 
aspiration. These problems can lead to psychosocial symptoms including distress, 
embarrassment and social withdrawal [3, 4].  
Treatment is usually determined by clinician experience and includes the use of 
anticholinergic medications, botulinum toxin injection, radiotherapy and surgery [2, 3, 
5 - 19]. However, studies evaluating these therapies are limited by lack of blinding, 
few participants and the use of outcome measures not designed for patients with 
ALS [7, 13, 20 - 22]. It should also be noted that the treatment of sialorrhea by any of 
these medications is unlicensed in the UK. Patients with ALS also often suffer from 
problems with the collection of thick secretions in their throat and respiratory tract. 
These thick secretions may develop or be exacerbated following treatments for 
excessive thin saliva [6].  
In the absence of evidence-based guidelines, sharing experience and practice 
amongst clinicians is an approach which can be used to develop a better 
understanding of the merits of available treatments. In this paper we build on work 
from a previous survey of clinician opinion about secretion management by 
McGeachan 7 
 
detailing the treatment approaches that are actually being used by neurologists 
working at ALS care centres across the UK [2].   
The aims of this descriptive study were to identify: 
x which therapies were used to manage oropharyngeal secretion problems. 
x how the different treatment options were used in combination. 
x treatment approaches in patients with symptoms resistant to initial management. 
x the type and impact of adverse effects in patients being treated for secretion 
problems. 
METHODS AND PATIENTS 
We conducted a retrospective cohort study, involving a review of the notes of 
patients identified to have a secretion problem. A case report form (CRF) [Appendix 
1] for recording individual secretion management regimens was circulated to 23 ALS 
care centre physicians with from across the UK. These clinicians were asked to 
complete a case report, using information recorded in the clinical record, for each 
consecutive patient they saw in clinic with a current or previous secretion problem, 
during the period between 01/12/2012 and 01/04/2013. This approach reduced recall 
and selection bias.  
A secretion problem was defined as: 
x Excessive saliva in a pDWLHQW¶VPRXWKZKLFKPD\FDXVHGURROLQJ 
x 7KHVHQVDWLRQRIWKLFNHUVHFUHWLRQVLQWKHSDWLHQW¶VWKroat which results in a 
choking-like discomfort.  
Data was collected from the clinical notes of patients attending clinics with a new 
secretion problem, and from patients attending clinics where they were followed up 
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for an existing secretion problem. Descriptive statistics were used to present the data. 
The treatments prescribed to patients with a secretion problem reported in the notes 
were recorded. When the notes contained details of patient attendance for follow up 
of a secretion problem, at any point during their illness, the side effects and the 
perceived benefit on symptoms of any treatment reported to the clinician were 
recorded in the case report form. In some cases there was no record concerning the 
effect on symptoms, these cases have been omitted from the descriptive statistic of 
the effect of treatment on symptoms. 
RESULTS 
During the census period 119 patients, who had at some point during their illness 
experienced a secretion problem, attended clinics. A case report form was 
completed following a notes review of all 119 patients. The time period covered 
ranged from 01/12/2012 to 01/04/2013. Nineteen of the 23 approached clinicians 
returned case report forms. Patient demographics are shown in Table 1.  The types 
of secretion problems experienced by patients were reported as: a problem solely 
with excessive saliva in 48 patients (40%); a problem solely with thicker secretions in 
27 (23%); and a combination of both types of secretion problem in 44 (37%). 
Problems with excessive saliva were reported to have been managed with 
anticholinergic drugs and salivary gland botulinum toxin injections. We identified five 
different types of anticholinergic drug used to manage problems in the 92 patients 
who were reported to have an excessive saliva problem. These were hyoscine 
hydrobromide/ scopolamine (transdermal patch or oral preparation), oral 
amitriptyline, atropine (sublingual drops, transdermal patch, or tablets), oral 
propantheline, and oral glycopyrronium bromide/ glycopyrrolate. The doses of 
these anticholinergics was commonly adjusted, either because an initial dose 
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was not providing sufficient symptomatic improvement, or in an attempt to 
reduce side effects.  
The most common first line treatment used to manage problems with excessive 
saliva was the prescription of an anticholinergic, used in all 92 patients. 72 of the 92, 
patients had been prescribed an anticholinergic at a previous appointment and had 
an effect on symptoms recorded at a follow up appointment.  An improvement in 
symptoms was recorded in 44 (61%) of these 72 patients, while in 28 (39%) it was 
recorded that the initial anticholinergic had not improved symptoms. In addition to 
these 72 patients, a further seven patients had been seen again since the 
prescription of an initial anticholinergic, but the effect of this treatment on symptoms 
had not been recorded. Side effects were reported in 43 (54%) of the 79 patients 
seen again. For 13 of the 92 patients no follow up data was available owing to the 
fact that their excessive saliva problem was first identified at the clinic visit during the 
data collection period. Figure 1 describes why not all patients who were prescribed 
an anticholinergic had outcome data recorded. 
The most frequently used first line anticholinergics were hyoscine patches (56), 
amitriptyline (15) and atropine drops (11). Symptoms were reported to have 
improved in patients following treatment with each of these of first line 
anticholinergics, with rates ranging from 54% to 89% [Figure 2].  
Of the 28/72 patients (39%) whose symptoms were reported to not have improved 
following an initial anticholinergic, 22 tried treatment with another anticholinergic. 21 
of the 22 had an outcome on symptoms recorded, only 4 (19%) of whom had any 
symptomatic improvement documented in their notes following instigation of the 
second anticholinergic. Sixteen patients were given a combination of two 
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anticholinergics after a first anticholinergic was reported to improve symptoms but 
not sufficiently to adequately control the problem over time. Of the 11 with an effect 
on symptoms recorded, five patients symptoms had improved (45%) and six (55%) 
had not. Seven of the 13 (54%) patients who had been seen again since starting 
combination anticholinergic therapy had adverse effects of this treatment 
documented in their notes. Three of these patients had not yet been seen again 
since the addition of a second anticholinergic and two had returned to clinic but the 
treatments effect on symptoms was not reported. Two patients went on to be 
prescribed three anticholinergics in combination. 
Different anticholinergic medications were prescribed on 161 occasions as a first, 
second, third or fourth line treatment for excessive saliva. Overall, anticholinergic 
treatment was recorded as improving symptoms in a proportion of patients ranging 
from 43% to 63% [Figure 3]. Whilst atropine drops and hyoscine patches were 
generally used first line, glycopyrronium was generally used as a second line 
treatment [Figure 4]. The doses of anticholinergics which were prescribed were 
highly variable [Table 2]. The commonly used hyoscine patch was usually prescribed 
as either a full (n=54) or a half (n=10) 1mg patch per 72 hours. Symptomatic 
improvement was recorded in all seven patients with an outcome recorded after 
starting half a patch. 
Undesired anticholinergic side effects reported included drying of the oral cavity, 
confusion, drowsiness and urinary retention [Table 3]. In addition, hyoscine patches 
were reported to cause a skin reaction at the patch site in 22% of patients [Table 3], 
leading to treatment discontinuation in 18% of those using hyoscine patches.  One 
patient was reported to have tried to control patch related skin reactions by applying 
topical steroid to the site of the reaction, enabling them to persist with the patch. 
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Overall 33% of patients discontinued hyoscine patches due to intolerable adverse 
effects. Sublingual atropine drops and oral glycopyrronium had lower reported rates 
of adverse effects, 24% and 29% respectively, compared to the 60% reported for 
hyoscine patches [Table 3].  
Botulinum toxin was used in 17/119 (14%) of patients with a secretion problem 
across 10 centres. In 14/17 patients (82%) botulinum toxin was used as a third line 
or later agent. Two patients received these injections under ultrasound guidance, 
and the time between the decision to give botulinum toxin injections and its 
administration varied from same day administration to 12 weeks later.  In total, three 
brands (Dysport, Neurobloc, and Botox A) and 12 different dosing regimens of 
botulinum toxin were used, including injection of both parotid and submandibular 
glands and parotid gland injections alone. The doses of botulinum toxin ranged from 
60 units of Dysport to 3000 units of Neurobloc [Table 4]. Despite being used in 
situations where symptoms were uncontrolled by anticholinergics, symptomatic 
improvement was documented in 8 (57%) of the 14 patients who had a symptom 
outcome recorded. Three patients had not been seen again since treatment with 
botulinum toxin. 
Of the 17 patients who received initial treatment with botulinum toxin injections, 
seven had already opted to receive additional injections and five had chosen to 
discontinue injections following just one treatment. The reason for discontinuation 
was unacceptable side effects in one patient, inadequate symptom control in two, a 
combination of inadequate symptom control and unacceptable side effects in one, 
and one patient unable to attend clinic.  Two patients continued to use 
anticholinergic medication alongside botulinum toxin injections for µtop up¶ symptom 
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control in between botulinum toxin injections. Three patients used carbocisteine 
syrup alongside botulinum toxin injections to combat thickened secretions. 
Of the 14 patients who were followed up after salivary gland botulinum toxin 
injections, 50% experienced adverse effects. This included two cases of 
deteriorating bulbar function, which LQWKHFOLQLFLDQ¶VRSLQLRQ was not due to disease 
progression. One of these cases followed injections to the parotid and 
submandibular glands and one after injections only into the parotid glands alone. 
 
Problems with thick secretions were also frequently reported to be a problem in this 
study population. In total 71 (60%) patients had reported thick secretions, in the 
absence of excessive thin secretions in 27 (23%) patients, or alongside this problem 
in 44 (37%) patients, possibly as a consequence of treatment with anticholinergic 
drugs or botulinum toxin.  Carbocisteine syrup was prescribed to 45 of these 
patients, 19 of whom only ever used carbocisteine, 9 of whom started carbocisteine 
first and then were also given anticholinergics for a subsequent thin secretion 
problem, and 17 of whom started an anticholinergic drug first and had carbocisteine 
added at a later date. In total symptomatic relief with carbocisteine was reported in 
27 of 31 patients (87%) with a documented outcome. 12 of these 31 patients only 
had a problem with thick secretions, all 12 (100%) had a documented improvement. 
15 (79%) of the 19 patients with both thick and thin secretion problems reported 
symptomatic improvement. In total, seven patients (19%) reported adverse effects 
when using carbocisteine including constipation (6%), excessive dryness of the 
mouth (6%), vomiting (2%), worsening of thin secretion problems (2%), and further 
deterioration of thick secretion problems (2%). Conservative measures were also 
commonly used to manage thick secretions [Table 4]. 
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Forty-six (39%) received conservative therapies, directed either at excessive saliva 
or thickened secretions. This included the use of suctioning, reported as  useful in 15 
(68%) of  22 patients where it was used, and maintaining adequate hydration, which 
was reported to be useful for all 6 of the patients in whom this intervention was 
documented [Table 4]. 
 
 
DISCUSSION 
In the absence of a cure for ALS, an important aspect of management is to control 
symptoms in order to maximise quality of life [6, 23]. The objective of this study was 
to explore the current management of saliva related problems by experienced 
clinicians at ALS centres in the UK.  
In general, the approach with anticholinergic medication sensibly appeared to 
be to adjust the dose to maximise benefits whilst minimising side effects. 
Hyoscine patches were overall the most frequently used therapy for excessive saliva, 
a choice which is often made because of the ease of use [2]. However hyoscine 
patches were frequently associated with adverse effects (60%), in particular, a skin 
reaction to the patch. The rate of hyoscine patch discontinuation due to adverse 
effects was 33%, often due to this skin reaction, considerably higher than the 13% 
discontinuation rate reported in a previous study of hyoscine patch use in children 
[24]. The suggestion that topically applied steroids could reduce this skin reaction 
may be a simple method to improve tolerability. As anticholinergics are so commonly 
associated with adverse effects and symptomatic improvement was reported at 
lower doses, it is most appropriate to consider their introduction at a low dose and to 
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titrate up as necessary against tolerance and effect. The use of glycopyrronium was 
generally preferred as second line. Further consideration could be given to this 
treatment as a first line option, especially given its relatively low rates of adverse 
effects, in part due to its poor penetration of the blood brain barrier [25]. 
Interestingly, of those patients whose symptoms did not improve with the first 
anticholinergic, only 19% had a symptomatic improvement if an alternative was tried 
subsequently. Further work is needed to determine which treatments are appropriate 
if an initial anticholinergic is ineffective. In comparison, 45% of patients reported 
symptomatic improvement when they started a second anticholinergic alongside 
their initial anticholinergic, when the first was reported to have provided significant 
but insufficient symptomatic control. Side effects were reported in 54% of such 
patients, a rate similar to that seen overall with anticholinergics. The switching and 
combination of anticholinergics was common place in this study, but is not well 
discussed in the literature and deserves further exploration [3, 6, 19]. It would also 
be useful to identify the common factors in patients who do not respond well or are 
intolerant to anticholinergics. 
In line with the limited available recommendations for saliva management, clinicians 
primarily chose botulinum toxin to treat patients with symptoms inadequately 
controlled by anticholinergic treatment [5, 19]. The 57% rates of symptomatic 
improvement reported in this study support the use of this treatment in such patients. 
There was a vast range of practice in the dose and injection site. The biological 
activity of Dysport is 50 times that of Neurobloc meaning that the most commonly 
prescribed dose of Dysport (100 Units) has twice the activity of the most commonly 
prescribed dose of Neurobloc (2500 units) [26]. With such variety in dosing and 
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injection sites it was not possible to consider differences in efficacy, side effects and 
safety profiles of this treatment. 
With the use of botulinum toxin, there is concern regarding a consequential 
deterioration in bulbar function [2], such a deterioration was reported in 14% of 
patients in this study. Despite greater anatomical distance between the parotid 
glands and the bulbar muscles compared to the submandibular glands, deterioration 
in bulbar function was also reported following isolated parotid gland injections. 
Bulbar deterioration could be a result of disease progression. However, in these 
cases the clinician had specifically documented that the post injection deterioration in 
function was, in their opinion, a consequence of botulinum toxin. The safety and long 
term efficacy of botulinum toxin injections in this setting needs to be further assessed 
to enable clinicians to judge the risks and benefits for their patients.  
Whilst there are studies suggesting that salivary gland irradiation may be an effective 
treatment, its use was not reported in this study [27]. Additionally, no surgical options 
were used which may reflect the invasive nature of these interventions and the frailty 
of this patient group. 
37% of patients were suffering from both thick and thin secretion problems. 
Furthermore, thickened secretions were one of the most commonly reported side 
effects of the treatments for excessive saliva. Carbocisteine was the preferred 
medication for managing thickened secretions often supplemented with conservative 
therapies, such as the use of saline nebulisers. A balance must be struck between 
the management of the different types of secretion difficulties. It would be useful for 
future studies to identify optimal practice for patients with different oral secretion 
profiles. 
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Despite remaining relatively unaddressed in many reviews and guideline articles [3, 
6, 5, 19], the use of conservative measures was often reported as part of the 
management for both thick and thin secretions. These are largely simple 
interventions which can be considered at the early stages of a secretion problem. A 
review of sialorrhoea management by Hockstein et al. in 2005 highlights a number of 
possible conservative measures [21]. 
This was a retrospective study. In the absence of a standardised follow up or 
outcome measure for patients with secretion problems, it was not possible to 
determine the extent of any symptomatic improvement or severity of any adverse 
effect. Moreover, it is possible that not all side effects were reported to the physician 
and so rates may have been higher than reported. As a result, it is not possible to 
compare different treatments.  
A previous study of UK secretion management estimated that the centres invited to 
participate in this study cared for 73% of the patients with a new diagnosis of ALS in 
2012 [2]. However, this study only represents clinicians managing secretion 
problems in the UK and therefore neglects treatments such as radiotherapy and 
tracheostomy which are commonly used outside of the UK [28, 29].  
Conclusion 
Simple data has been presented in this study to provide baseline information about 
the treatments in use in the UK. We hope this data will will facilitate effective design 
of further studies to determine which treatment options are most effective and best 
tolerated for managing oropharyngeal secretion problems in ALS. 
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Table Legend 
Table 1: Summary of the demographics of the patients whose secretion problem 
management was recorded in this study. 
Table 2: Summary of the dose variation of the treatments prescribed for the 
management of oral secretions. 
Table 3: Rates of reported adverse effects in patients receiving treatment for 
excessive saliva.  
Table 4: Summary of the relative merits of the various conservative measures for 
secretion management and the type of secretion problem they were used to treat. 
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Figure Legend 
Figure 1: Availability of outcome data for when patients received a first 
anticholinergic: Summarising why not all patients who were prescribed an 
anticholinergic had efficacy data recorded. 
 
Figure 2: Proportion of patients who had a documented symptomatic 
improvement when receiving a first line anticholinergic for excessive saliva: 
Summarising the percentage of patients, out of the patients who had an outcome to 
treatment recorded in their notes (improvement or no improvement), whose 
symptoms were documented to have improved when using each anticholinergic. 
 
 
Figure 3: Proportion of patients who had a documented symptomatic 
improvement when receiving a treatment for excessive saliva: Summarising the 
percentage of patients, out of the patients who had an outcome to treatment 
recorded in their notes (improvement or no improvement), whose symptoms were 
documented to have improved when using each anticholinergic. 
 
Figure 4: Frequency of the various anticholinergics prescribed for secretion 
management: Summarising the number of times each anticholinergic was 
documented to have been prescribed to patients for the control of a secretion 
problem. Data is broken down to present the frequency each anticholinergic was 
prescribed as a 1st, 2nd or 3rd line or later treatment. 
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Tables: 
Table 1: Patient demographics  (n=119) 
Age Mean (Range) 64 years (40-86 years) 
  
Gender Male 50% 
  
Disease Duration Median (Range) 2.2 years (0.1 ± 15.9) 
  
Bulbar onset disease   50% 
Gastrostomy  44% 
NIV  18% 
Cough Assist  7% 
 
Last ALSFRS-R Score 
when available (n=88) 
 
Mean (Range)                   28/48 (3-45) 
 
Last ALSFRS-R bulbar 
subscore 
when available (n=88) 
 
 
Mean (Range) 4.7/12 (0-12) 
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Table 2: Summary of the dose variation of the treatments prescribed for 
the management of oral secretions 
  Number of 
different doses 
Dose range Most common 
dose 
Anticholinergic 
medications 
   
Hyoscine Patch 
(n=69) 
8 ¼ of 1mg patch per 72 
hours ± 1 ½  1mg patch per 
24 hours 
1mg patch per 72 
hours 
 
Oral Hyoscine 
(n=8) 
4 0.15mg TDS ± 0.3mg TDS 0.3mg TDS 
Amitriptyline 
(n=25) 
13 10mg ON ± 175mg  10mg ON 
 
Sublingual 
Atropine Drops 
(n=24) 
15 1% solution 2 drops ON ± 
1% solution 2 drops QDS 
1-2 drops TDS 
Glycopyrronium 
(n=19) 
13 02.mg BD ± 3mg TDS 1mg TDS 
 
Botulinum 
Toxin 
  
        Total dose given i.e.  split between glands 
Dysport 12 60U ± 400U 100U 
Neurobloc 6 1000U ± 3000U 2500U 
BOTOX A 2 14U ± 100U Each used once 
 
Mucolytics 
Carbocisteine 7 125mg TDS ± 750mg TDS 375mg TDS 
*U = Units; ON = Once nightly; BD = twice daily; TDS = 3 times daily; QDS = 4 times 
daily 
*The 175mg dose of amitriptyline was prescribed by GP for emotional lability. 
* Infrequently prescribed anticholinergic preparations (n<3) have been omitted from 
this table 
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* One patient (14%) using oral hyoscine reported an excessively dry mount (n=7) 
* Infrequently prescribed anticholinergic preparations (n<3) have been omitted from 
this table 
 
  
Table 3: Rates of reported adverse effects in patients receiving treatment for 
excessive saliva: 
 Hyoscine 
Patches 
(n=57) 
Amitriptyline 
(n= 25) 
Atropine 
drops 
(n= 21) 
Oral 
Glycopyrronium 
(n= 17) 
Botulinum 
toxin 
injections 
(n=14) 
Excessively Dry 
Mouth 6 (11%) 5 (20%) 3 (14%) 2 (12%) 1(7%) 
Thickened 
Secretions 10 (18%) 3 (12%) 2 (10%) 2 (12%) 5 (36%) 
Skin Reaction 12 (22%) 0 0 0 0 
Confusion 5 (9%) 0 0 0 0 
Drowsiness 6 (9%) 8 (32%) 0 0 0 
Dizziness 4 (5%) 2 (8%) 0 0 0 
Light headed 4 (5%) 2 (8%) 0 0 0 
Nausea 3 (5%) 0 0 0 0 
Urinary 
Retention 
1 (2%) 1 (4%) 0 0 0 
Bulbar 
dysfunction 
0 0 0 0 2 (14%) 
 
Total Number 
(%) 
 
34 (60%) 
 
 
12 (48%) 
 
 
6 (29%) 
 
 
4 (24%) 
 
 
7 (50%) 
 
Proportion who 
discontinued 
due to adverse 
effects 
 
 
33% 
 
 
12% 
 
 
6% 
 
 
5% 
 
 
13% 
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Table 4: Summary of the relative merits of the various conservative measures 
for secretion management and the type of secretion problem they were used to 
treat 
  Total 
Used 
Useful Maybe 
Useful 
Not 
useful 
  
 
   
Therapies for 
managing 
excessive 
secretions 
Speech therapy 22 12 (52%) 6 (26%) 5 
(22%) 
 
Suction 
 
22 
 
15 (68%) 
 
3 (14%) 
 
4 
(18%) 
 
Swallow 
reminders 
 
11 
 
6 (55%) 
 
4 (36%) 
 
1 (9%) 
 
Positioning collar 
 
9 
 
3 (33%) 
 
3 
(33%) 
 
3 
(33%) 
 
Therapies for 
thinning out 
secretions 
 
Steam 
nebulisers 
 
19 
 
11 (58%) 
 
4 (21%) 
 
4 
(21%) 
 
Fruit juice 16 7 (43%) 7 (43%) 2 
(14%) 
 
Papaya 
 
9 
 
5 (56%) 
 
3 (33%) 
 
1 
(11%) 
 
Hydration 
 
6 
 
6 
(100%) 
 
0 0 
  
Swabs 
 
5 
 
3 (60%) 
 
0 
 
2 
(40%) 
 
